Navigation Links
Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
Date:10/18/2010

MORRISTOWN, N.J., Oct. 18 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV.  Distribution of the product has commenced.

As the first company to file an ANDA that contained a paragraph IV certification for Ambien® CR 6.25mg, Actavis has been awarded 180-day exclusivity to market this product.

Zolpidem Tartrate Extended-Release Tablets 6.25mg, the generic equivalent of Ambien® CR 6.25mg by Sanofi-Aventis, had US sales of approximately $129 million for the 12 months ending June 30, 2010, according to IMS Health.

Commenting on the new approval, Doug Boothe, CEO of Actavis in the US, said:

"The approval of Zolpidem ER Tablets 6.25mg offers a significant value to our customers and patients.  This approval, along with the first-to-file exclusivity, also underscores Actavis' emphasis and commitment to bringing complex controlled-release products to the marketplace."

Please see prescribing information at www.actavis.us/Zolpidem.

About Actavis Inc.

Actavis Inc. is the US subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market.  Based in Morristown, NJ, Actavis has US manufacturing facilities in Elizabeth, NJ and Lincolnton, NC.  Actavis also has research and development facilities in Owings Mills, MD and Sunrise, FL.

About Actavis Group

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals.  The company has operations in 40 countries, with more than 10,500 employees.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future.  There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements.  These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
2. Actavis Receives FDA Approval of Atomoxetine HCl Capsules
3. Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
4. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
5. Actavis Launches Generic Version of Flomax(R) In The U.S.
6. Actavis Receives Approval of Alprazolam ODT in the U.S.
7. ISTA Pharmaceuticals Receives FDA Approval for BROMDAY™
8. Watsons Generic Version of Lotrel ® Receives FDA Approval
9. EntreMed Receives Notice of NASDAQ Compliance
10. Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
11. Greenways PrimeSUITE Receives ONC-ATCB 2011/2012 Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016 http://www.researchandmarkets.com/research/fqx6nz/global_skin ... "Global Skin Protective Equipment Market 2016-2020" report ... http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the addition of the ... report to their offering. --> ... announced the addition of the "Global Skin ...
(Date:2/8/2016)...   Intarcia Therapeutics, Inc. today announced the ... the newly created role of Vice President, Head of ... two decades of leadership experience at leading pharmaceutical, biotechnology, ... medical center. Most recently Dr. Yee served as VP, ... Head Medical Officer at AstraZeneca, where he led medical ...
(Date:2/8/2016)... 2016  The University of Michigan Health System in ... as part of the development of four new operating ... in the U.S. to start using new top-of-the-line neurosurgical ... chair of neurosurgery. --> Karin Muraszko ... The BrightMatter technology from Synaptive Medical – a ...
Breaking Medicine Technology:
(Date:2/8/2016)... AUSTIN (PRWEB) , ... February 08, 2016 , ... Remember ... next time. , According to Perry A~, author of “Calcium Bentonite Clay” the ... a key role in balancing and detoxifying the body. , A former motivational speaker, ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with ... time to make a change in public health,” states Carole Baggerly, Director of ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Guruji Mahendra Kumar ... 10th and 11th, 2016 in honor of his birthday on February 10th. During ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
(Date:2/6/2016)... ... 2016 , ... US Sports Camps is proud to sponsor the Bay Area ... top non-profit leaders, ultimate organizations, and coaches from around the US. The theme for ... Program Director of Youth and Education, describes this year YUCC as “an important conversation ...
Breaking Medicine News(10 mins):